병원약사회지 (Journal of Korean Society of Health-System Pharmacists)

  • 제35권4호
  • /
  • Pages.475-483
  • /
  • 2018
  • /
  • 1226-640X(pISSN)
  • /
  • 2466-2143(eISSN)
한국병원약사회 (The Korean Society of Health-System Pharmacists)
권호 표지

항암제 과민반응에 대한 탈감작요법의 경험

  • 강민경 (서울아산병원 약제팀) ;
  • 김태범 (서울아산병원 약물감시센터)
  • 발행 : 2018.12.31

⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Medina PJ, Shord SS. Cancer Treatment and chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a Pathophysiologic Approach. 8th ed. New York: McGraw-Hill, 2011:2192-2228.
  2. 이주연, 정재우, 강혜련 등. 자발적 약물유해반응 데이터베이스를 이용한 항암제 유해사례 현황 분석. 대한내과학회지. 2013;85(4):385-395.
  3. Ruggiero A, Triarico S, Trombatore G et al. Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer. Eur J Clin Pharmacol. 2013;69(10):1739-1746. https://doi.org/10.1007/s00228-013-1546-0
  4. Limsuwan T, Castells MC. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf. 2010;9(1):39-53. https://doi.org/10.1517/14740330903446936
  5. 김수진. 약물 알레르기(Drug Allergy). 병원약사회지. 2011;28(4):400-409.
  6. Drain KL, Volcheck GW. Preventing and managing drug-induced anaphylaxis. Drug Saf. 2001;24(11);843-853. https://doi.org/10.2165/00002018-200124110-00005
  7. Hong DI, Dioun AF. Indications, protocols, and outcomes of drug desensitization for chemotherapy and monoclonal antibodies in adults and children. J Allergy Clin Immunol Pract. 2014;2(1):13-19 https://doi.org/10.1016/j.jaip.2013.11.007
  8. Cernadas JR, Brockow K, Romano A et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Alllergy. 2010;65(11):1357-1366. https://doi.org/10.1111/j.1398-9995.2010.02441.x
  9. 이서영, 양민석, 정재우 등. 항암제 과민반응에 대한 탈감작요법의 최신지견. Allegy Asthma Respir Dis. 2013;1(4):295-302. https://doi.org/10.4168/aard.2013.1.4.295
  10. Navo M, Kunthur A, Badell ML et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol. 2006;103(2):608-613. https://doi.org/10.1016/j.ygyno.2006.04.002
  11. Liu A, Fanning L, Chong H et al. Desensitization regimens for drug allergy: state of the art in the 21st century. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2011;41(12):1679-1689. https://doi.org/10.1111/j.1365-2222.2011.03825.x
  12. Polyzos A, Tsavaris N, Gogas H et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology. 2009;76(1);36-41. https://doi.org/10.1159/000178163
  13. Caiado J, Picard M. Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. Curr Allergy Asthma Rep. 2014;14(8):451 https://doi.org/10.1007/s11882-014-0451-7
  14. Wong JT, Ling M, Patil S et al. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract. 2014;2(1):40-45. https://doi.org/10.1016/j.jaip.2013.08.011
  15. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D et al. Desensitizing oxaliplatin-induced fever: a case report. J Investing Allergol Clin Immunol. 2013;23(6):435-436.
  16. Schwartz JR, Bandera C, Bradley A et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants'Hospital. Gynecol Oncol. 2007;105(1):13-18. https://doi.org/10.1016/j.ygyno.2006.10.059
  17. Gaducci A, Tana R, Teti G et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2008;18(4):615-620. https://doi.org/10.1111/j.1525-1438.2007.01063.x
  18. Weiss RB, Donehower RC, Wiemik PH et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263-1268. https://doi.org/10.1200/JCO.1990.8.7.1263
  19. Wiernik PH, Schwartz E, Strauman J et al, Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987;47(2):2486-2493.
  20. Markman M, Kennedy A, Webster K et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18(1):102-105. https://doi.org/10.1200/JCO.2000.18.1.102
  21. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc. 2002;23(3):205-208.
  22. Castells MC, Tennant NM, Sloane DE et al. Hypersenstivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574-80. https://doi.org/10.1016/j.jaci.2008.02.044
  23. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: Standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99(2):393-399. https://doi.org/10.1016/j.ygyno.2005.06.028
  24. Feldweg AM, Lee CW, Matulonis UA et al. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96(3):824-829. https://doi.org/10.1016/j.ygyno.2004.11.043
  25. Brennan PJ, Bouza TR, Hsu FI et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259-1266. https://doi.org/10.1016/j.jaci.2009.09.009